Divi's Laboratories — Q3 FY24
Divis Laboratories reported a steady Q3 FY24 with PAT of INR 358 crore on total income of INR 1,950 crore.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY24
Custom synthesis growth from Big Pharma projects in coming quarters
Two large custom synthesis projects are now at full production capacity, with revenue contribution expected to be visible in the next quarters.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1